Quest Gains Control of Ciphergen, Stays Mum on Three Dxs In Development

Diagnostics behemoth Quest will develop three diagnostic assays selected from Ciphergen s pipeline, but neither company would name the three assays to be carried on to further development and commercialization. But if Ciphergen s performances are any gauge, its ovarian cancer diagnostic is in the running. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.